[1] |
郭红梅,韩彦彦. 川崎病病因及其发病机制研究进展[J]. 医学综述,2015,21(23):4260-4262.
|
[2] |
SHULMAN S T,ROWLEY A H.Kawasaki disease:insights into pathogenesis and approaches to treatment[J]. Nat Rev Rheumatol,2016,11(8):475-482.
|
[3] |
NEWBURGER J W,TAKAHASHI M,BURNS J C.Kawasaki disease[J]. J Am Coll Cardiol,2016,67(14):1738-1749.
|
[4] |
刘琳,丁文惠. 川崎病的心脏损害及治疗现状[J]. 中国心血管杂志,2013,18(4):311-313.
|
[5] |
耿玲玲,苗峰,李小青. 不完全川崎病合并冠状动脉瘤的临床特点分析[J]. 中国全科医学,2018,21(30):3761-3764.
|
[6] |
SONOBE T,ASO S,IMADA Y,et al.The incidence of coronary artery abnormaliety in incomplete Kawasaki disease[J]. Pediatr Res,2003,49(4):421-426.
|
[7] |
MARIA C M,GIOVANNI C.Atypical and incomplete Kawasaki disease[J]. Ital J Pediatr,2015,41(Suppl 2):A45.
|
[8] |
NEWBURGER J W,TAKAHASHI M,GERBER M A,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the committee on rheumatic fever,endocarditis,and Kawasaki disease,council on cardiovascular disease in the young,American Heart Association[J]. Pediatrics,2004,114(6):1708-1733.
|
[9] |
江载芳,申坤玲,沈颖. 诸福棠实用儿科学[M]. 8版. 北京:人民卫生出版社,2014:698-705.
|
[10] |
张乾忠. 不典型川崎病的临床表现和诊断[J]. 中国实用儿科杂志,2006,21(10):728-730.
|
[11] |
孙兴珍. 川崎病患儿血清C反应蛋白、肿瘤坏死因子-α与心肌酶谱变化和冠状动脉损伤的关系[J]. 中华实用儿科临床杂志,2008,23(21):1659-1660.
|
[12] |
HONKANEN V E,MCRINDLE B W,LAXER R M,et al.Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease[J]. Pediatr Cardiol,2003,24(2):122-126.
|
[13] |
KOBAYASHI T,INOUE Y,TAKEUEHI K,et al.Prediction of intravenouse immunoglobulin unresponsiveness in patients with Kawasaki disease[J]. Circulation,2006,113(22):2606-2612.
|
[14] |
MASUZAWA Y,MORI M,HARA T,et al.Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease[J]. Ther Apher Dial,2015,19(2):171-177.
|
[15] |
莫坚,王玲,蒙海强. 川崎病患儿血浆凝血四项及血小板变化的意义[J]. 实用儿科临床杂志,2010,25(9):658-659.
|